Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 4Recurrence 2Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, B-Cell 1Leukemia 1Klatskin Tumor 1Hematologic Neoplasms 1Hematologic Diseases 1Fallopian Tube Neoplasms 1Disease Progression 1Disease 1Cholangiocarcinoma 1Breast Neoplasms 1Blood Protein Disorders 1Bile Duct Neoplasms 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 98Fluorouracil 90Capecitabine 86Dexamethasone 81Radiotherapy 80Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Leucovorin 64Drug Therapy 64Cetuximab 60Erlotinib Hydrochloride 56Sorafenib 53atezolizumab 52Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × ricolinostat × Clear all
NCT01997840 2025-03-04

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1/2 Terminated
103 enrolled 21 charts
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡